These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 20703033)

  • 1. Antivascular endothelial growth factor for choroidal neovascularization in pathologic myopia.
    Battaglia Parodi M; Iacono P; Bandello F
    Dev Ophthalmol; 2010; 46():73-83. PubMed ID: 20703033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-vascular endothelial growth factor for myopic choroidal neovascularization.
    Ng DS; Kwok AK; Chan CW
    Clin Exp Ophthalmol; 2012; 40(1):e98-e110. PubMed ID: 21902785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Laser photocoagulation, photodynamic therapy, and intravitreal bevacizumab for the treatment of juxtafoveal choroidal neovascularization secondary to pathologic myopia.
    Parodi MB; Iacono P; Papayannis A; Sheth S; Bandello F
    Arch Ophthalmol; 2010 Apr; 128(4):437-42. PubMed ID: 20142520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FACTORS INFLUENCING NEED FOR RETREATMENT AND LONG-TERM VISUAL OUTCOME AFTER INTRAVITREAL BEVACIZUMAB FOR MYOPIC CHOROIDAL NEOVASCULARIZATION.
    Ng DS; Kwok AK; Tong JM; Chan CW; Li WW
    Retina; 2015 Dec; 35(12):2457-68. PubMed ID: 26035400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravitreal bevacizumab therapy on an as-per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia: 2-year outcomes of a prospective case series.
    Iacono P; Parodi MB; Papayannis A; Kontadakis S; Sheth S; Bandello F
    Retina; 2011 Oct; 31(9):1841-7. PubMed ID: 21775926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic factors of eyes with naïve subfoveal myopic choroidal neovascularization after intravitreal bevacizumab.
    Yang HS; Kim JG; Kim JT; Joe SG
    Am J Ophthalmol; 2013 Dec; 156(6):1201-1210.e2. PubMed ID: 24075429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Choroidal neovascularization in pathologic myopia.
    Dave V; Narayanan R
    Am J Ophthalmol; 2010 Nov; 150(5):752; author reply 752-3. PubMed ID: 21036211
    [No Abstract]   [Full Text] [Related]  

  • 8. Intravitreal bevacizumab for extrafoveal choroidal neovascularization secondary to pathologic myopia.
    Parodi MB; Iacono P; Papayannis A; Kontadakis S; Cascavilla ML; Zucchiatti I; Bandello F
    Retina; 2013 Mar; 33(3):593-7. PubMed ID: 23190919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in aqueous vascular endothelial growth factor and pigment epithelial-derived factor levels following intravitreal bevacizumab injections for choroidal neovascularization secondary to age-related macular degeneration or pathologic myopia.
    Chan WM; Lai TY; Chan KP; Li H; Liu DT; Lam DS; Pang CP
    Retina; 2008 Oct; 28(9):1308-13. PubMed ID: 18728623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravitreous bevacizumab to treat subfoveal choroidal neovascularization in highly myopic eyes: short-term results.
    Ruiz-Moreno JM; Gomez-Ulla F; Montero JA; Ares S; Lopez-Lopez F; Rodriguez M; Fernandez M
    Eye (Lond); 2009 Feb; 23(2):334-8. PubMed ID: 18064056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subfoveal Choroidal Thickness Changes Following Anti-Vascular Endothelial Growth Factor Therapy in Myopic Choroidal Neovascularization.
    Ahn SJ; Park KH; Woo SJ
    Invest Ophthalmol Vis Sci; 2015 Sep; 56(10):5794-800. PubMed ID: 26325418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study.
    Chan WM; Lai TY; Liu DT; Lam DS
    Ophthalmology; 2007 Dec; 114(12):2190-6. PubMed ID: 17599414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Choroidal neovascularization in pathologic myopia: intravitreal ranibizumab versus bevacizumab--a randomized controlled trial.
    Gharbiya M; Giustolisi R; Allievi F; Fantozzi N; Mazzeo L; Scavella V; Gabrieli CB
    Am J Ophthalmol; 2010 Mar; 149(3):458-64.e1. PubMed ID: 20172072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myopic choroidal neovascularization.
    Ruiz-Moreno JM; López-Gálvez MI; Donate J; Gomez-Ulla F; García-Arumí J; García-Layana A; Sellés I; Reche J; Montero JA; Pazos B; Zapata MA; Pastor JC
    Ophthalmology; 2011 Dec; 118(12):2521-3. PubMed ID: 22136676
    [No Abstract]   [Full Text] [Related]  

  • 15. Short-term effects of intravitreal bevacizumab for subfoveal choroidal neovascularization in pathologic myopia.
    Hernández-Rojas ML; Quiroz-Mercado H; Dalma-Weiszhausz J; Fromow-Guerra J; Amaya-Espinosa A; Solís-Vivanco A; Reyna-Castelán E; Abraham-Marín M; Martínez-Castellanos MA; Aiello LP
    Retina; 2007; 27(6):707-12. PubMed ID: 17621179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. One-year outcome of two different initial dosing regimens of intravitreal ranibizumab for myopic choroidal neovascularization.
    Kung YH; Wu TT; Huang YH
    Acta Ophthalmol; 2014 Dec; 92(8):e615-20. PubMed ID: 24924911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CHOROIDAL THICKNESS AND CHORIORETINAL ATROPHY IN MYOPIC CHOROIDAL NEOVASCULARIZATION WITH ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
    Lee JH; Lee SC; Kim SH; Koh HJ; Kim SS; Byeon SH; Lee CS
    Retina; 2017 Aug; 37(8):1516-1522. PubMed ID: 27798519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular endothelial growth factor inhibitor use and treatment approach for choroidal neovascularization secondary to pathologic myopia.
    Pakzad-Vaezi K; Mehta H; Mammo Z; Tufail A
    Expert Opin Biol Ther; 2016 Jul; 16(7):873-81. PubMed ID: 26985834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis and treatment guideline for myopic choroidal neovascularization due to pathologic myopia.
    Ohno-Matsui K; Ikuno Y; Lai TYY; Gemmy Cheung CM
    Prog Retin Eye Res; 2018 Mar; 63():92-106. PubMed ID: 29111299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia.
    Lai TY; Chan WM; Liu DT; Lam DS
    Retina; 2009 Jun; 29(6):750-6. PubMed ID: 19357555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.